Armen Shanafelt
President bei Abshanafelt Advisory
Profil
Armen Shanafelt brings over 29 years of operational experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures.
Previous to joining Lilly Ventures in 2009, Armen held leadership and executive positions in the R&D organizations of DNAX Research Institute, Bayer Pharmaceuticals, Roche Diagnostics, and Eli Lilly and Company.
Armen currently serves as a director on the boards of Aeglea BioTherapeutics (NASDAQ: AGLE), Aileron Therapeutics (NASDAQ: ALRN), Protagonist Therapeutics (NASDAQ: PTGX), Surface Oncology (NASDAQ: SURF), Sutro Biopharma and Symic Biomedical.
He is a Kauffman Fellow (Class 14).
Armen received his B.S.
Degree in Chemistry and Physics from Pacific Lutheran University, and his Ph.D.
in Chemistry from the University of California, Berkeley.
Aktive Positionen von Armen Shanafelt
| Unternehmen | Position | Beginn |
|---|---|---|
| Abshanafelt Advisory | President | 01.01.2021 |
Ehemalige bekannte Positionen von Armen Shanafelt
| Unternehmen | Position | Ende |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Director/Board Member | 08.09.2023 |
| SPYRE THERAPEUTICS, INC. | Chairman | 01.01.2019 |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Private Equity Investor | 01.12.2020 |
| AILERON THERAPEUTICS, INC. | Director/Board Member | 19.06.2019 |
Protagonist Pty Ltd.
 Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | Director/Board Member | 01.06.2019 |
Ausbildung von Armen Shanafelt
| Pacific Lutheran University | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| SUTRO BIOPHARMA, INC. | Health Technology |
| AILERON THERAPEUTICS, INC. | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| PROTAGONIST THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Health Technology |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | Health Technology |
Symic Bio, Inc.
 Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | Health Technology |
Symic Holdings LLC
 Symic Holdings LLC BiotechnologyHealth Technology Symic Holdings LLC develops new category of therapeutics. The company was founded by John Paderi, Kate Stuart and Alyssa Panitch and is headquartered in Emeryville, CA. | Health Technology |
Roche Diagnostics Corp.
 Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN. | Health Technology |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Finance |
HemaQuest Pharmaceuticals, Inc.
 HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA. | Health Technology |
| DNAX Research, Inc. | |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
| Abshanafelt Advisory |
